ARV-471

Pfizer's $1B protein degradation bet yields 3% response rate in Arvinas' midphase breast cancer trial
Fierce Biotech
Tue, 11/22/22 - 11:00 am
Pfizer
protein degradation
Arvinas
clinical trials
breast cancer
ARV-471